Human Papillomavirus (HPV)
No Results
No Results
processing….
Human papillomavirus (HPV) produces epithelial tumors of the skin and mucous membranes. The current classification system for HPV, which is based on similarities in genomic sequences, generally correlates with the 3 clinical categories applied to HPV infection:
Anogenital or mucosal (further subclassified as latent [asymptomatic], subclinical, or clinical)
Nongenital cutaneous
Epidermodysplasia verruciformis (see the images below)
See Pediatric Vaccinations: Do You Know the Recommended Schedules?, a Critical Images slideshow, to help stay current with the latest routine and catch-up immunization schedules for 16 vaccine-preventable diseases.
The clinical history and presentation of HPV infection vary according to the anatomic area involved. The predilection of certain viral genotypes for infecting certain epidermal sites largely determines areas of involvement. Conditions with which HPV is associated include the following:
Anogenital warts (condylomata acuminata): These are usually found near moist surfaces (eg, perianal area, vaginal introitus, vagina, labia, and vulva) but may also be found on dry surfaces (eg, penile shaft); they may be smooth and papular or keratotic; they generally are not painful but can be associated with pruritus or bleeding
Cervical disease (eg, low-grade squamous intraepithelial lesion [LGSIL] or high-grade squamous intraepithelial lesion [HGSIL])
Anal cancer: About 50% of men who are homosexual and have anal squamous cell carcinoma (SCC) have a history of anorectal warts; however, only 20% of women with SCC and men who are not homosexual have this history
Nonanogenital mucosal disease (eg, oral warts, respiratory papillomas, and focal epithelial hyperplasia [Heck disease])
Nongenital cutaneous disease (eg, common cutaneous warts [verruca vulgaris], flat warts [verruca plana] and Bowenoid papulosis)
Epidermodysplasia verruciformis
Physical findings vary, depending on the tissues involved, and may include the following:
Typical condylomata are discrete, papillary, cauliflower-like lesions that involve multiple sites on moist surfaces
Keratotic warts are often seen on dry surfaces such as the labia majora
Discrete papules 1-3 mm in size can present on the shaft of the penis
Cervical intraepithelial lesions may be found upon examination of the cervix
Subclinical infection may be present, with tiny, slightly raised areas felt or visualized on the vagina or cervix
See Clinical Presentation for more detail.
The diagnosis of most cutaneous and external genital warts can be made through clinical examination or with application of acetic acid and biopsy. In genital intraepithelial neoplasia, it is essential to determine the extent of disease through careful inspection and colposcopy.
Laboratory studies that may be considered include the following:
Cervical cytologic testing with the Papanicolaou (Pap) test to screen for cervical neoplasia (guidelines for cervical cancer screening now include a delay in the initiation of screening and longer intervals between subsequent screens [1] )
HPV DNA testing (eg, with Hybrid Capture II or polymerase chain reaction [PCR] assay) for detection of HPV and posttreatment follow-up of cervical intraepithelial neoplasia
The acetic acid test: This test can be used in conjunction with colposcopy to examine cervical lesions; however, it is reserved for suspicious lesions and should not be used for routine screening
In some cases, tissue biopsy can be used to confirm HPV infection. A biopsy is recommended for the following scenarios:
Women with a history of vulvar dysplasia
Postmenopausal women
Women in whom medical therapy fails
Clinical doubt about the diagnosis
Histologic findings that can help elucidate the diagnosis include the following:
Common cutaneous warts: Marked hyperkeratosis, acanthosis, parakeratosis, and papillomatosis; warts can be distinguished from other papillomas by the presence of koilocytes, vertical columns of parakeratosis, and foci of clumped keratohyaline granules
Condyloma acuminatum: Disruption of the epidermis with hyperkeratosis, coarse keratohyaline granules, and koilocytes in a prominent granular layer; the epidermis or mucosa of flat condylomata demonstrates acanthosis
Bowenoid papulosis: Psoriasiform hyperplasia and hyperkeratosis of the epidermis, with increased mitotic figures at all epidermal levels and keratinocytes displaying enlarged pleomorphic and hyperchromic nuclei
See Workup for more detail.
All medicines used to treat HPV disease are applied topically; they should not be applied to mucosal surfaces and should not be used to treat dysplastic lesions, squamous cell carcinoma, verrucous carcinoma, or Bowenoid papulosis. The following 2 broad categories of medications are effective:
Immune response modifiers (eg, imiquimod and interferon alfa): These are primarily used in treatment of external anogenital warts or condylomata acuminata
Cytotoxic agents: These include both antiproliferative drugs (eg, podofilox, podophyllin, and 5-fluorouracil [5-FU]) and chemodestructive or keratolytic agents (eg, salicylic acid, trichloroacetic acid [TCA], and bichloracetic acid [BCA]); the latter are the only agents recommended for treatment of nongenital cutaneous warts
Sinecatechins ointment is another option.
Surgical interventions are commonly considered when a large number of warts are present, a large area is affected, or the patient has refractory disease. Overall, physical destruction or excision has been more effective in eradicating genital warts than medical therapy. Primary surgical therapy can often be accomplished in the office and includes the following options:
Cryosurgery
Electrosurgery (electrodesiccation or a loop electrosurgical excision procedure [LEEP])
Simple surgical excision with a scalpel, scissors, or curette
Alternative surgical procedures include the following:
Carbon dioxide laser ablation
Cavitron Ultrasonic Surgical Aspiration (CUSA)
Mohs surgery
Vaccines are available for prevention of HPV infection, and recommended vaccination schedules have been outlined.
See Treatment and Medication for more detail.
HPV produces epithelial tumors of the skin and mucous membranes. More than 100 HPV types are known, and the genomes of more than 80 have been completely sequenced. People with multiple sexual partners and those who already have persistent HPV infection are at increased risk for acquiring additional HPV strains. [2, 3, 4, 5] The current classification system, which is based on similarities in genomic sequences, generally correlates with the 3 clinical categories applied to HPV:
Anogenital or mucosal
Nongenital cutaneous
Epidermodysplasia verruciformis (EV)
The mucosal HPV infections are classified further as latent (asymptomatic), subclinical, or clinical. Clinical lesions are grossly apparent, whereas latent infections are detected only with tests for viral DNA. Subclinical lesions are identified by application of 3-5% acetic acid and inspection under magnification. Most HPV infections are latent; clinically apparent infections usually result in warts rather than malignancies.
Infections due to HPV are common and lead to a wide variety of clinical manifestations that involve the epidermal surfaces. Condylomata acuminata (genital warts) are generally recognized as benign proliferations of the anogenital skin and mucosa resulting from HPV infection. Genital warts are transmitted by sexual contact. Approximately two thirds of individuals who have sexual contact with an infected partner develop genital warts. The exact incubation time is unknown but estimated to be 3 weeks to 8 months. [6, 7]
Despite the generally benign nature of these proliferations, certain types of HPV can place patients at a high risk for anogenital cancer. [8, 9, 10] Some have also been implicated in laryngeal and oral cancer and some lung cancers.
HPV types 6 and 11 are typically labeled as low risk because infection with these types has low oncogenic potential and usually results in the formation of condylomata and low-grade precancerous lesions. HPV types 16 and 18 have emerged as the high-risk types of HPV because they are responsible for most high-grade intraepithelial lesions that may progress to carcinomas, particularly those in the anogenital or mucosal category.
HPV infection alone does not cause malignant transformation of infected tissue. Cofactors, such as tobacco use, ultraviolet radiation, pregnancy, folate deficiency, and immune suppression, have been implicated in this process.
Physicians’ understanding of the natural history of HPV disease has significantly improved over the last 20 years, but key issues remain unanswered. Topics requiring further research include HPV age-specific outcomes, the likelihood of progression or regression of disease, and factors important in the acquisition of immunity following infection. [11]
Papillomaviruses are nonenveloped viruses of icosahedral symmetry with 72 capsomeres that surround a genome containing double-stranded circular DNA with approximately 8000 base pairs. Their genome is divided into the following 3 major functional regions:
The early (E) region codes for 6 nonstructural genes, several of which are associated with cellular transformation.
The late (L) region codes for 2 structural proteins, L1 and L2, that form the capsid
The long control region is a noncoding region that regulates replication and gene function
Papillomaviruses are highly species-specific and do not infect other species, even under laboratory conditions. Humans are the only known reservoir for HPV. Papillomaviruses have never been grown in vitro but have been characterized by molecular methods. These viruses are classified by the molecular similarity of their genetic material and are assigned a genotype number.
Although some overlap exists, most papillomaviruses have distinct anatomic predilections, infecting only certain epidermal sites, such as skin or genital mucosa. The virus has the potential to integrate into host DNA, frequently with the loss of the early regulatory function.
HPV infects the basal keratinocyte of the epidermis, presumably through disruptions of the skin or mucosal surface. At this location, the virus remains latent in the cell as a circular episome in low copy numbers. Autoinoculation of virus into opposed lesions is common. Spread of HPV infection is usually through skin-associated virus and not blood-borne infection. Cell-mediated immunity (CMI) probably plays a significant role in wart regression; patients with CMI deficiency are particularly susceptible to HPV infection and are notoriously difficult to treat. [12]
Papillomaviruses are thought to have 2 modes of replication:
Stable replication of the episomal genome in basal cells
Runaway, or vegetative, replication in more differentiated cells to generate progeny virus
As the epidermal cells differentiate and migrate to the surface, the virus is triggered to undergo replication and maturation, and at the keratitic layer, the virus is present in high copy numbers and is shed in the exfoliation cells. The process of virus replication alters the character of the epidermis, resulting in cutaneous or mucosal excrescences known as warts.
Note the figures below detailing the mechanisms of action for HPV.
Although all cells of a lesion contain the viral genome, the expression of viral genes is tightly linked to the state of cellular differentiation. Most viral genes are not activated until the infected keratinocyte leaves the basal layer. Production of virus particles can occur only in highly differentiated keratinocytes; therefore, virus production occurs only at the epithelial surface where the cells are ultimately sloughed into the environment.
HPV infections have not been shown to be cytolytic; rather, viral particles are released as a result of degeneration of desquamating cells. The HPV virus can survive for many months and at low temperatures without a host; therefore, an individual with plantar warts can spread the virus by walking barefoot.
Viral multiplication is confined to the nucleus. Consequently, infected cells exhibit a high degree of nuclear atypia. Koilocytosis (from Greek koilos “empty”) describes a combination of perinuclear clearing (halo) with a pyknotic or shrunken (raisinoid) nucleus and is a characteristic feature of productive papillomavirus infection.
Numerous viral genotypes have the potential to transform cells and are associated with epidermal malignancies. In benign or low-risk HPV lesions, such as those typically associated with HPV types 6 and 11, the HPV genome exists as a circular episomal DNA separate from the host cell nucleus. In malignant lesions, the genomes of high-risk HPV types 16 and 18 are typically integrated into the host cell DNA. Integration of the viral genome into the host cell genome is considered a hallmark of malignant transformation.
HPV proteins E6 and E7 of high-risk serotypes have been shown to inactivate the host’s tumor suppressor proteins p53 and Rb, thereby resulting in unregulated host cell proliferation and malignant transformation.
The definitive cause of anogenital warts is HPV infection. [8, 9, 10, 13] The HPV capsid lacks an envelope, which makes the organism very stable and resistant to various treatments. No serologic typing is available, because of the lack of consistent in vitro culture methods. Typing of HPV is based on genotype, which generally is determined by molecular hybridization using molecularly cloned HPV DNA of known type as the standard. Two HPV are of different types when their DNA hybridize (bind) less than 50% as efficiently to each other as to themselves.
The nearly 40 types of HPV that have been found in genital warts [14] are highly host-specific. These viruses do not infect laboratory animals and are not susceptible to acyclovir. In addition, HPV types demonstrate a high degree of site specificity, with some types only found on certain parts of the skin or mucous membranes. As a rule, HPV types causing common warts of the skin do not infect moist epithelium, and vice versa.
Multiple clinical associations with unique genotypes of HPV have been documented. Some of these associations are listed in the Table below.
Table 1. Diseases Associated With Specific HPV Types (Open Table in a new window)
Nongenital Cutaneous Disease
HPV Type
Common warts (verrucae vulgaris)
1, 2, 4, 26, 27, 29, 41, 57, 65, 75-78
Plantar warts (myrmecias)
1, 2, 4, 60, 63
Flat warts (verrucae planae)
3, 10, 27, 28, 38, 41, 49
Butcher’s warts (common warts of people who handle meat, poultry, and fish)
1-4, 7, 10, 28
Mosaic warts
2, 27, 57
Ungual squamous cell carcinoma
16
Epidermodysplasia verruciformis (benign)
2, 3, 10, 12, 15, 19, 36, 46, 47, 50
Epidermodysplasia verruciformis (malignant or benign)
5, 8-10, 14, 17, 20-25, 37, 38
Nonwarty skin lesions
37, 38
Nongenital Mucosal Disease
HPV Type
6, 11
Squamous cell carcinoma of the lung
6, 11, 16, 18
Laryngeal papilloma (recurrent respiratory papillomatosis) [15]
2, 6, 11, 16, 30, 40, 57
6, 11
Maxillary sinus papilloma
57
Squamous cell carcinoma of the sinuses
16, 18
Conjunctival papillomas
6, 11
Conjunctival carcinoma
16
Oral focal epithelial hyperplasia (Heck disease)
13, 32
16, 18
16, 18
Squamous cell carcinoma of the esophagus
16, 18
Anogenital Disease
HPV Type
1-6, 10, 11, 16, 18, 30, 31, 33, 35, 39-45, 51-59, 70, 83
16, 18, 34, 39, 40, 42, 45
16, 18, 31, 34
Giant condylomata (Buschke-Löwenstein tumors)
6, 11, 57, 72, 73
Unspecified intraepithelial neoplasia
30, 34, 39, 40, 53, 57, 59, 61, 62, 64, 66-69
Low-grade squamous intraepithelial lesions (LGSIL)
6, 11, 16, 18, 26, 27, 30, 31, 33-35, 40, 42-45, 51-58, 61, 62, 67-69, 71-74, 79, 81-84
High-grade squamous intraepithelial lesions (HGSIL)
6, 11, 16, 18, 31, 33, 35, 39, 42, 44, 45, 51, 52, 56, 58, 59, 61, 64, 66, 68, 82
6, 11, 16, 18
Carcinoma of vagina
16
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73, 82
Carcinoma of anus
16, 31, 32, 33
Carcinoma in situ of penis (erythroplasia of Queyrat)
16
16, 18
HPV infection alone does not cause malignant transformation of infected tissue. Cofactors, such as tobacco use, ultraviolet radiation, pregnancy, folate deficiency, and immune suppression, have been implicated in this process, particularly in the anogenital-mucosal category. Patients receiving immunosuppressive drugs and patients with defects in cell-mediated immunity, including those infected with HIV, are especially susceptible to HPV infections.
Sexual activity
A direct correlation exists between anogenital HPV infection and measures of sexual activity, such as the age of first intercourse and the lifetime number of sexual partners.
Women with a history of high-grade squamous intraepithelial lesions (HGSIL) of the cervix or invasive squamous cell carcinoma (SCC) of the cervix are at increased risk for subsequent development of invasive cancer in other tissues of the anogenital-mucosal category, particularly vaginal and anal carcinoma (relative risks, 5.6 and 4, respectively).
Anal cancer has been strongly associated with male homosexuality and with specific male practices, such as engaging in receptive anal intercourse; relative risk is 33. However, the overall disease prevalence is higher in women than in men, with a female-to-male ratio of 1.5:1.
Tobacco smoking
Women who smoke tobacco have an increased risk of developing cervical neoplasia. Measurable amounts of a potent carcinogen, as well as several compounds from cigarette smoke, have been identified in the cervical mucus of females who smoke. These agents are likely to play a role in the increased prevalence of HPV malignant transformation observed in patients who smoke tobacco.
Oral contraceptive use
Women who take oral contraceptives for longer than 5 years have an increased relative risk of developing cervical carcinoma. This risk declines after oral contraceptive use is stopped, and no risk is demonstrated in women who took these agents for less than 5 years.
Chewing Indian betel quid
A high incidence of oral cancer associated with HPV infection has been demonstrated in India among patients who chew betel quid. This stimulant is made from the leaves of the betel plant and is used in a manner similar to chewing tobacco.
Ultraviolet and x-ray irradiation
EV is particularly susceptible to ultraviolet (UV) and x-ray irradiation; therefore, patients with EV should avoid activities that unnecessarily expose them to these forms of radiation.
The United States has no reporting system for HPV infections. Infections and the development of warts appear to be common throughout life. In general, genital HPV infection is considered to have become dramatically more frequent over the past several decades.
In the United States, young adults aged 15-24 years account for approximately one half of new HPV infections each year. [18] The frequency of genital infections is associated with the number of sexual partners and the age of sexual debut. Patients receiving immunosuppressive drugs and patients with defects in cell-mediated immunity, including those infected with the human immunodeficiency virus (HIV), are especially susceptible to developing HPV infections.
Using data and self-collected cervicovaginal specimens from 4150 females in 4 consecutive National Health and Nutrition Examination Surveys (2003-2006), Hariri et al found HPV present in 42.5% of US females aged 14-59 years. The highest rate of infection is among young females aged 20-24 years. [19]
The population-based incidence of genital warts was estimated at 106 cases per 100,000 population in Rochester, Minnesota (for 1975-1978) [20] and at 160 cases per 100,000 population in Manitoba, Canada (for 1992), [21] with the highest incidence rate in residents aged 20-24 years.
Figures from 5 Blue Cross/Blue Shield Health Plans projected an incidence of 105 cases per 100,000 population (for 2004). [22] They estimated 340,000 cases nationwide in 2004, with an economic burden of more than $220 million. [22]
These figures differed from those indicated by data collected from STD clinics and private practitioners’ offices. Using data from these sources, the US Centers for Disease Control and Prevention (CDC) suggested much higher figures: an estimated incidence of more than 6 million new patients a year in the United States (in 2008) and an estimated prevalence of more than 20 million. [23, 24, 25, 26, 27] By way of comparison, the CDC estimated that 1.6 million people have genital herpes and 1.6 million have chlamydia or gonorrhea.
According to the “National Disease and Therapeutic Index: United States, 1966–2010, the Initial visits to physicians’ offices for STD,” the increasing trend of HPV infection, after peaking at 351,000 visits in 1987, went down in the following 10 years. Unfortunately, the increasing trend resumed again and reached the highest level ever in 2006 (422,000 visits) before dropping down to 357,000 in 2010.
Studies diagnosing HPV infection through by visual inspection of genital condylomata report the lowest prevalences. The highest prevalences are reported by studies typing HPV from exfoliated genital tract cells. As many as 75% of individuals who have sexual contact with an HPV-infected partner will develop external genital warts. [28]
Condylomata acuminata are clinically apparent in 1% of the sexually active population. Molecular studies indicate that 10-20% of men and women aged 15-49 years have been exposed to HPV. The prevalence of HPV is higher in certain populations. A prevalence of 4-13% has been reported by sexually transmitted disease (STD) clinics.
Several investigators report an increased prevalence of anogenital HPV infections during pregnancy. The prevalence of condyloma increases from the first to third trimester and then decreases significantly post partum. The risk of condyloma acuminatum in pregnancy is 2-fold. Vulvar condylomata can rarely become large enough to obstruct labor. Cesarean delivery decreases, but does not completely prevent, HPV transmission with development of laryngeal papillomas in the infant. [29, 30, 31, 32]
HPV infection causes virtually all cases of cervical cancer. [33, 34] In cervical neoplasias, the HPV genome can be detected in more than 95% of tumors. No deaths due to cervical cancer have been documented in women younger than 20 years. The United States National Cancer Institute publishes data on the prevalence of worldwide cervical cancer via their online database.
The incidence of cervical cancer has decreased dramatically during the last century because of the implementation of the Papanicolaou test (Pap Test, or Pap smear), beginning in the 1930s and 1940s. However, between 1990 and 2001, the annual number of estimated new invasive cervical cancers remained relatively constant (13,500 and 12,900, respectively). In the United States, 2.5 million women are estimated to have an annual cytologic diagnosis of a low-grade cervical cancer precursor.
The percentages of other cancers caused by oncogenic HPV are as follows [34] :
Anal cancer – 90%
Vulvar cancer – 40%
Vaginal cancer – 40%
Oropharyngeal cancer – 12%
Oral cancer – 3%
Globally, HPV infection is the most common STD. [35, 36] Genital warts have affected as many as 30 million individuals worldwide. A study in Finland in the mid-1980s found that the annual incidence of cytologic cervical HPV infection was 7%. [37] A study of Finnish males determined that 6.5% had evidence of HPV in exfoliative cells obtained from the urethra and genital epithelium. [38]
In many lesser-developed countries, cervical cancer is the most common cancer among women because of the lack of effective screening programs that monitor cervical cytology by Pap smear. [39] However, a single round of HPV screening has been demonstrated to be far superior to conventional cytology in reducing the incidence of cervical cancer morbidity and mortality. [40]
The prevalence of high-risk HPV in women with normal cervical cytology varies among the different regions of the world. Although the global HPV prevalence was estimated to be approximately 12%, higher prevalences were noted in sub-Saharan Africa (24%), eastern Europe (21.4%), and Latin America (16.1%). [41]
In many developing nations, cervical cancer is the leading cause of cancer mortality among women. Worldwide, it is the second most common cause of cancer mortality among women. The World Health Organization (WHO) estimates that 570,000 new cases of cervical cancers occurred globally in 2018, and approximately 311,000 women died of cervical cancer during the same year. [42]
People of any age may develop common warts. HPV infects more than 50% of sexually active adults. Genital infection generally occurs during the sexually active period in a person’s life, and infections increase with the number of sexual partners.
The prevalence of anogenital mucosal HPV infections is highest among college-aged women and men. The prevalence of HPV infection stratified by age in US females is as follows [43] :
Age 14-59 years – 26.8%
Age 14-19 years – 24.5%
Age 20-24 years – 44.8%
Age 25-29 years – 27.4%
Age 30-39 years – 27.5%
Age 40-49 years – 25.2%
Age 50-59 years – 19.6%
Thus, the highest rates of genital HPV infection are in young, sexually active females. This incidence is independent of the number of lifetime sexual partners. Most of these infections (90%) are transient. [44, 45, 46] An estimated 5.6% of sexually active adults in the United States aged 18-59 years have been diagnosed with genital warts by a medical provider. [47]
A cytologic screening of the cervix in more than 400,000 women supported a higher incidence of HPV in young women. This study found that the rate of HPV infection in women younger than 30 years is double that in women older than 30 years. [48]
The reason for the higher prevalence in younger women is not completely understood. Some investigators hypothesize that older women have fewer sexual partners and, consequently, less exposure to HPV. An alternative theory is that by age 30 years, women have acquired immunity to HPV. [49]
The presence of genital condyloma in the pediatric population presents a diagnostic and therapeutic challenge. [50] Vertical transmission of HPV can occur via in utero exposure to amniotic fluid or transmission of HPV from the maternal genital tract.
An incubation period of several months is usually required between virus infection at delivery and clinical manifestations in the infant. The average latency period is 3 months, but periods as long as 20 months have been reported. [51] Cases of childhood condylomata outside a reasonable incubation period after vertical transmission should arouse suspicion of child abuse. Treatment of condyloma in the infant includes excision under general anesthesia or the use of podophyllin. [52]
Nongenital cutaneous warts are more common among teenagers and adults who work as meat, poultry, and fish handlers. The incidence approaches 10% in child and young adult populations. However, nongenital cutaneous warts rarely occur in people younger than 5 years and usually regress within 2 years.
EV develops at an average age of onset of 6 years. Beginning in the fourth decade of life, the lesions can undergo malignant transformation into invasive SCC.
The overall prevalence of HPV in women is reported to be 22-35%. In men, the prevalence is reported to be 2-35%, depending on the sexual practices of the population being studied. However, a well-defined population study found the female-to-male ratio to be 1.4:1, [20] and CDC reports demonstrated that this disease affects females more frequently than males.
The prevalence of condyloma acuminatum seems to be similar in men and women. A study from an STD clinic found that 13% of men and 9% of women had condylomata acuminata. [23] HPV infections are reported more frequently in US college females [53] than in male counterparts. This presumed higher incidence of HPV infection in females may be the result of detection of HPV infection in cytologic smears performed for cervical cancer screening. Females seek medical care for genital warts more frequently than men do. [26]
In the United States, African Americans have a rate of HPV infection that is 1.5 times higher than their white counterparts. However, most studies indicate that no racial predilection exists for the acquisition of genital warts.
Dinh et al analyzed data from the 1999-2004 National Health and Nutrition Examination Surveys, which collected data from a random sample of the United States civilian population. These investigators reported that the prevalence of genital warts was higher in non-Hispanic whites than in other racial or ethnic groups. [47] One US survey reported that among women, the prevalence of HPV infection due to any HPV type was 39% for non-Hispanic blacks, and 24% for non-Hispanic whites and Mexican Americans. [43]
From 1987 to 1991, the age-adjusted cervical cancer death rate reported by the US National Cancer Institute was higher among black women than among white women, with a ratio of 6:1.
HPV infection primarily involves the basal epithelial cells. As a result, both recurrences and regressions are common. Prognosis is good, and most cases of genital warts are amenable to treatment. Patients who do not develop immunity to HPV can develop potentially serious sequelae.
Genital warts may spontaneously regress, remain unchanged, or increase in size. Treatment of these lesions does not affect the development of cervical cancer. Approximately two thirds of patients with nongenital cutaneous warts experience a spontaneous regression within 2 years; however, some new warts may appear.
HPV infection of the vulva can result in the development of vulvar intraepithelial neoplasia (dysplasia) or squamous cell carcinoma of the vulva. Most research indicates that HPV infection is strongly associated with the development of cervical dysplasia and cervical carcinoma. HPV confers more than 99% of the attributable risk for the development of cervical dysplasia. [54] Vaginal dysplasia and vaginal cancer are also associated with HPV exposure.
Histologic evidence of HPV infection on a cervical Pap smear is similar to mild dysplasia. This subclinical disease often spontaneously regresses.
A direct correlation exists between anogenital HPV infection and measures of sexual activity, such as the age of first intercourse and the lifetime number of sexual partners. Women with a history of HGSIL of the cervix or invasive SCC of the cervix are at increased risk for subsequent development of invasive cancer in other tissues of the anogenital-mucosal category, particularly vaginal and anal carcinoma. In these patients, the relative risk of vaginal carcinoma is 5.6, and the risk of anal carcinoma is 4.
Women who are immunocompromised as a result of immunosuppressive drug therapy or HIV infection are at higher risk for persistent disease. These women are more likely to develop dysplasia or cancer of the vulva, vagina, or cervix.
Anal cancer has been strongly associated with male homosexuality and specific male practices, such as engaging in receptive anal intercourse. Relative risk is 33. However, the overall disease prevalence is higher in women than in men, with a female-to-male ratio of 1.5:1.
Men who are infected with HPV are at risk for genital warts. The 24-month risk varied from 57.9% in men who were infected with HPV type 6 or type 11 to 2% in men who were infected with other HPV types. [55]
Patients who are immunosuppressed, particularly those with cutaneous malignant lesions, have a much higher incidence of EV-HPV infection than the general population. These lesions can undergo malignant transformation. About 10% of patients with EV originate from consanguineous marriages, suggesting an autosomal recessive mode of inheritance (see Epidermodysplasia Verruciformis).
Most patients with EV experience progression of their disease in the third or fourth decades of life. Malignant transformation usually arises from actinic keratoses, particularly in patients who are exposed to irradiation. Patients who remain protected from x-rays and sun exposure generally have satisfactory health.
As many as 20% of patients with genital warts have other sexually transmitted diseases concurrently (Rochester, Minnesota). [22] In an Australian sexual health clinic, 5% of genital wart patients were found to also have chlamydia and/or gonorrhea. [56]
Treatment of genital warts can be difficult and lengthy. Patient expectations should be set appropriately. Counsel patients on their risk of infectivity to others, and advise them of their increased risk of having acquired other STDs. Remind them that genital warts resolve spontaneously in 20-30% of women within 3 months. [28]
Educating women, particularly those who are socially and economically disadvantaged, about behaviors that enhance sexual risk reduction has a proven benefit in reducing the incidence of STDs. Reducing the incidence of STDs potentially could decrease HPV transmission and, consequently, the incidence of cervical carcinoma.
Inform patients that genital HPV is an STD and that the only way to prevent HPV infection is to avoid direct contact with the virus, which is transmitted by skin-to-skin contact. Instruct them to use condoms with vaginal, anal, or oral sex because the virus may be found in the semen in the absence of visible warts. Remind them that latex condoms offer some, but not complete, protection from transmission.
The benefit of evaluating sex partners of patients with genital warts has been apparent. Several consort studies documented that 30% of female consorts and 80% of male consorts had HPV infection. Usually, the same type of HPV involved both parties, and often they were HPV 6, 11, 16, and 18. If the sexual partner has visible genital warts, sexual contact should be avoided until treatment is completed.
For patient education resources, see the Women’s Health Center, the Pregnancy Center, and the Cancer Center, as well as Genital Warts, Plantar Warts, and Pap Smear.
[Guideline] ACOG Committee on Practice Bulletins–Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol. 2009 Dec. 114(6):1409-20. [Medline].
Sanchez-Aleman MA, Uribe-Salas FJ, Lazcano-Ponce EC, Conde-Glez CJ. Human papillomavirus incidence and risk factors among Mexican female college students. Sex Transm Dis. 2011 Apr. 38(4):275-8. [Medline].
Castle PE, Rodriguez AC, Burk RD, et al. Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis. 2011 Mar 15. 203(6):814-22. [Medline]. [Full Text].
Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011 Mar 12. 377(9769):932-40. [Medline]. [Full Text].
Chaturvedi AK, Katki HA, Hildesheim A, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011 Apr 1. 203(7):910-20. [Medline]. [Full Text].
Becker TM, Stone KM, Alexander ER. Genital human papillomavirus infection. A growing concern. Obstet Gynecol Clin North Am. 1987 Jun. 14(2):389-96. [Medline].
Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003 Feb 1. 157(3):218-26. [Medline].
Chuang TY. Condylomata acuminata (genital warts). An epidemiologic view. J Am Acad Dermatol. 1987 Feb. 16(2 Pt 1):376-84. [Medline].
Chuang TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum in Rochester, Minn, 1950-1978. II. Anaplasias and unfavorable outcomes. Arch Dermatol. 1984 Apr. 120(4):476-83. [Medline].
Nebesio CL, Mirowski GW, Chuang TY. Human papillomavirus: clinical significance and malignant potential. Int J Dermatol. 2001 Jun. 40(6):373-9. [Medline].
Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009 Jul 29. 9:119. [Medline]. [Full Text].
Rhea WG Jr, Bourgeois BM, Sewell DR. Condyloma acuminata: a fatal disease?. Am Surg. 1998 Nov. 64(11):1082-7. [Medline].
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997 May 5. 102(5A):3-8. [Medline].
Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen Hz, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010 May 25. 401(1):70-9. [Medline]. [Full Text].
Lee LA, Cheng AJ, Fang TJ, Huang CG, Liao CT, Chang JT, et al. High incidence of malignant transformation of laryngeal papilloma in Taiwan. Laryngoscope. 2008 Jan. 118(1):50-5. [Medline].
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov. 11(11):1048-56. [Medline].
Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003 Jan 13. 88(1):63-73. [Medline]. [Full Text].
Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004 Jan-Feb. 36(1):6-10. [Medline].
Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011 Aug 15. 204(4):566-73. [Medline].
Chuang TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Arch Dermatol. 1984 Apr. 120(4):469-75. [Medline].
Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis. 2009 Jun. 36(6):380-6. [Medline].
Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin. 2009 Oct. 25(10):2343-51. [Medline].
Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988. 10:122-63. [Medline].
Nuovo GJ. Detection of human papillomavirus DNA in the lower genital tract. Infect Urol. 1994. 87-93.
Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis. 1998 Oct. 27(4):796-806. [Medline].
Fleischer AB Jr, Parrish CA, Glenn R, Feldman SR. Condylomata acuminata (genital warts): patient demographics and treating physicians. Sex Transm Dis. 2001 Nov. 28(11):643-7. [Medline].
Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis. 1999 Apr. 26(4 Suppl):S2-7. [Medline].
ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol. 2005 Apr. 105(4):905-18. [Medline].
Peng TC, Searle CP 3rd, Shah KV, Repke JT, Johnson TR. Prevalence of human papillomavirus infections in term pregnancy. Am J Perinatol. 1990 Apr. 7(2):189-92. [Medline].
Rando RF, Lindheim S, Hasty L, Sedlacek TV, Woodland M, Eder C. Increased frequency of detection of human papillomavirus deoxyribonucleic acid in exfoliated cervical cells during pregnancy. Am J Obstet Gynecol. 1989 Jul. 161(1):50-5. [Medline].
Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer. 1987 Aug 15. 40(2):198-201. [Medline].
Shah K, Kashima H, Polk BF, Shah F, Abbey H, Abramson A. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol. 1986 Dec. 68(6):795-9. [Medline].
Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995 Jun 7. 87(11):796-802. [Medline].
Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006 Aug 31. 24 Suppl 3:S3/11-25. [Medline].
Syrjanen K, Syrjanen S. Epidemiology of human papilloma virus infections and genital neoplasia. Scand J Infect Dis Suppl. 1990. 69:7-17. [Medline].
Pham TH, Nguyen TH, Herrero R, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer. 2003 Mar 20. 104(2):213-20. [Medline].
Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuously high sexual activity. Sex Transm Dis. 2000 Sep. 27(8):438-45. [Medline].
Hippelainen M, Syrjanen S, Hippelainen M, et al. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis. 1993 Nov-Dec. 20(6):321-8. [Medline].
Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2. 360(14):1385-94. [Medline].
Schiffman M, Wacholder S. From India to the world–a better way to prevent cervical cancer. N Engl J Med. 2009 Apr 2. 360(14):1453-5. [Medline].
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010 Dec 15. 202(12):1789-99. [Medline].
World Health Organization. Human papillomavirus (HPV) and cervical cancer. WHO. Available at https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. January 24, 2019; Accessed: February 5, 2019.
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007 Feb 28. 297(8):813-9. [Medline].
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12. 338(7):423-8. [Medline].
Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996 Oct. 174(4):679-89. [Medline].
Figueroa JP, Ward E, Luthi TE, Vermund SH, Brathwaite AR, Burk RD. Prevalence of human papillomavirus among STD clinic attenders in Jamaica: association of younger age and increased sexual activity. Sex Transm Dis. 1995 Mar-Apr. 22(2):114-8. [Medline].
Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999–2004. Sex Transm Dis. 2008 Apr. 35(4):357-60. [Medline].
Meisels A. Cytologic diagnosis of human papillomavirus. Influence of age and pregnancy stage. Acta Cytol. 1992 Jul-Aug. 36(4):480-2. [Medline].
Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis. 1995 Apr. 171(4):1026-30. [Medline].
Dempsey AF, Koutsky LA. National burden of genital warts: a first step in defining the problem. Sex Transm Dis. 2008 Apr. 35(4):361-2. [Medline].
Davis AJ, Emans SJ. Human papilloma virus infection in the pediatric and adolescent patient. J Pediatr. 1989 Jul. 115(1):1-9. [Medline].
Shelton TB, Jerkins GR, Noe HN. Condylomata acuminata in the pediatric patient. J Urol. 1986 Mar. 135(3):548-9. [Medline].
Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med. 1996 Apr 18. 334(16):1030-8. [Medline].
Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol. 2000 Jan. 19(1):16-28. [Medline].
Arima Y, Winer RL, Feng Q, Hughes JP, Lee SK, Stern ME, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis. 2010 Oct 15. 202(8):1181-4. [Medline].
Sturgiss EA, Jin F, Martin SJ, Grulich A, Bowden FJ. Prevalence of other sexually transmissible infections in patients with newly diagnosed anogenital warts in a sexual health clinic. Sex Health. 2010 Mar. 7(1):55-9. [Medline].
Barclay L. New guidance recommends HPV DNA test for primary screening. January 9, 2015. Medscape Medical News. WebMD Inc. Available at http://www.medscape.com/viewarticle/837832.
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015 Feb. 125(2):330-7. [Medline].
[Guideline] U.S. Preventive Services Task Force. Screening for Cervical Cancer. U.S. Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm. Accessed: August 29, 2012.
[Guideline] Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May-Jun. 62(3):147-72. [Medline].
Kalliala I, Anttila A, Dyba T, Hakulinen T, Halttunen M, Nieminen P. Pregnancy incidence and outcome among patients with cervical intraepithelial neoplasia: a retrospective cohort study. BJOG. 2012 Jan. 119(2):227-35. [Medline].
Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011 Nov 26. 378(9806):1868-73. [Medline].
Lee JK, Kim MK, Song SH, et al. Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples. Int J Gynecol Cancer. 2009 Feb. 19(2):266-72. [Medline].
Nelson R. FDA OKs HPV DNA Test for Primary Cervical Cancer Screening. Medscape Medical News. Apr 24 2014. [Full Text].
Auborn KJ, Carter TH. Treatment of human papillomavirus gynecologic infections. Clin Lab Med. 2000 Jun. 20(2):407-22. [Medline].
Beutner KR, Wiley DJ, Douglas JM, Tyring SK, Fife K, Trofatter K, et al. Genital warts and their treatment. Clin Infect Dis. 1999 Jan. 28 Suppl 1:S37-56. [Medline].
Bergman A, Bhatia NN, Broen EM. Cryotherapy for treatment of genital condylomata during pregnancy. J Reprod Med. 1984 Jul. 29(7):432-5. [Medline].
Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009 Dec. 114(6):1179-88. [Medline].
Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis. 2012 May 15. 205(10):1544-53. [Medline].
Genital warts and sexual abuse in children. American Academy of Dermatology Task Force on Pediatric Dermatology. J Am Acad Dermatol. 1984 Sep. 11(3):529-30. [Medline].
Diamantis ML, Bartlett BL, Tyring SK. Safety, efficacy & recurrence rates of imiquimod cream 5% for treatment of anogenital warts. Skin Therapy Lett. 2009 Jun. 14(5):1-3, 5. [Medline].
Garland SM, Waddell R, Mindel A, Denham IM, McCloskey JC. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS. 2006 Jul. 17(7):448-52. [Medline].
Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007. 67(15):2187-210. [Medline].
Welander CE, Homesley HD, Smiles KA, Peets EA. Intralesional interferon alfa-2b for the treatment of genital warts. Am J Obstet Gynecol. 1990 Feb. 162(2):348-54. [Medline].
Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condylomata acuminata. N Engl J Med. 1986 Oct 23. 315(17):1059-64. [Medline].
Monsonego J, Cessot G, Ince SE, Galazka AR, Abdul-Ahad AK. Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum. Genitourin Med. 1996 Apr. 72(2):111-4. [Medline]. [Full Text].
Bornstein J, Pascal B, Zarfati D, Goldshmid N, Abramovici H. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. Int J STD AIDS. 1997 Oct. 8(10):614-21. [Medline].
Yang J, Pu YG, Zeng ZM, Yu ZJ, Huang N, Deng QW. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis. 2009 Sep 21. 9:156. [Medline]. [Full Text].
Hellberg D, Svarrer T, Nilsson S, Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS. 1995 Jul-Aug. 6(4):257-61. [Medline].
Krebs HB. Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil. South Med J. 1990 Jul. 83(7):761-4. [Medline].
Basita CS, Atallah AN, Saconato, da Silva EMK. 5-FU for genital warts in non-compromised individuals. Cochrane Database of Systematic Reviews. John Wiley and Sons, Ltd; 2010. 4.
Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis. 1993 Nov-Dec. 20(6):344-5. [Medline].
Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. 2008 Jun. 111(6):1371-9. [Medline].
Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol. 2009 Mar. 200(3):233.e1-7. [Medline].
Langley PC. A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. J Med Econ. 2010 Mar. 13(1):1-7. [Medline].
Gilson RJ, Ross J, Maw R, Rowen D, Sonnex C, Lacey CJ. A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts. Sex Transm Infect. 2009 Dec. 85(7):514-9. [Medline].
Duus BR, Philipsen T, Christensen JD, Lundvall F, Sondergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med. 1985 Feb. 61(1):59-61. [Medline]. [Full Text].
Lipow M. Laser physics made simple. Curr Prob in Obstet Gynecol Fertil. 1986. 9:445-493.
Aynaud O, Buffet M, Roman P, Plantier F, Dupin N. Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment. Eur J Dermatol. 2008 Mar-Apr. 18(2):153-8. [Medline].
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) – NCT03158220. ClinicalTrials.gov. 2018 March 13; Accessed: 2018 Oct 11.
U.S. Food and Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. FDA News Release. 2018 Oct 05. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm.
Haug CJ. Human papillomavirus vaccination–reasons for caution. N Engl J Med. 2008 Aug 21. 359(8):861-2. [Medline].
Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008 Aug 21. 359(8):821-32. [Medline]. [Full Text].
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10. 356(19):1915-27. [Medline].
Catch-Up Immunization Schedule for Persons Aged 4 Months Through 18 Years Who Start Late or Who Are More Than 1 Month Behind. Centers for Disease Control and Prevention (CDC). Available at https://www.cdc.gov/vaccines/schedules/hcp/imz/catchup.html. 2018 Feb 06; Accessed: 2018 Oct 11.
Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years – United States, 2017. MMWR Morb Mortal Wkly Rep. 2018 Aug 24. 67 (33):909-917. [Medline]. [Full Text].
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21. 347(21):1645-51. [Medline].
Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005 May. 6(5):271-8. [Medline].
Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011 Dec. 87(7):544-7. [Medline].
Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009 Apr 1. 199(7):926-35. [Medline].
Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009 Dec. 85(7):499-502. [Medline].
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10. 356(19):1928-43. [Medline].
Brooks M. Real-World’ Study Confirms Value of HPV Vaccine in Women. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821591. Accessed: March 17, 2014.
Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014 Mar 4. 348:g1458. [Medline]. [Full Text].
Hitt E. Quadrivalent HPV vaccine appears safe, but skeptics remain. Medscape Medical News. Available at http://www.medscape.com/viewarticle/772019. Accessed: October 16, 2012.
Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012 Oct 1. 1-9. [Medline].
Neale T. No Clot Risk Seen With HPV Vaccine. Medscape Medical News. Available at http://www.medpagetoday.com/Cardiology/VenousThrombosis/46677. Accessed: July 14, 2014.
Scheller NM, Pasternak B, Svanstrom H, Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA. 2014 Jul. 312(2):187-8. [Medline].
Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3. 364(5):401-11. [Medline].
Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011 Oct 27. 365(17):1576-85. [Medline].
Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010 Dec. 10(12):845-52. [Medline].
Wawer MJ, Tobian AA, Kigozi G, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet. 2011 Jan 15. 377(9761):209-18. [Medline]. [Full Text].
[Guideline] Saslow D, Andrews KS, Manassaram-Baptiste D, Loomer L, Lam KE, Fisher-Borne M, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016 Sep. 66 (5):375-85. [Medline].
[Guideline] Swift D. Two HPV vaccine doses advised for children under age 15. Medscape Medical News. Available at http://www.medscape.com/viewarticle/870722. October 20, 2016;
Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. March 27, 2015. 64(11):300-304. [Full Text].
Lowes R. Just-Approved Gardasil 9 Packs More HPV/Cancer Protection. Medscape Medical News. Dec 10 2014. [Full Text].
FDA. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm. Accessed: Dec 18 2014.
Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc. December, 2015. Available at [Full Text].
Joura E, et al. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. Abstract (SS 8-4) presented at EUROGIN 2014 November 5, 2013.
VanDamme P, et al. Immunogenicity and safety of a novel 9-valent HPV L1 virus-like particle vaccine in boys and girls 9-15 years old; comparison to women 16-26 years old. Abstract (SS 8-5) presented at EUROGIN 2014 November 5, 2013.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Mar 23. 56:1-24. [Medline].
[Guideline] Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007 Jan-Feb. 57(1):7-28. [Medline].
[Guideline] FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May 28. 59(20):626-9. [Medline]. [Full Text].
Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011 Dec 23. 60(50):1705-8. [Medline].
FDA. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May 28. 59(20):630-2. [Medline].
Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 2003 Sep 15. 63(18):6032-41. [Medline].
Baldwin PJ, van der Burg SH, Boswell CM, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res. 2003 Nov 1. 9(14):5205-13. [Medline].
Grens K. HPV Tied to Higher Esophageal Cancer Risk. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/808770. Accessed: August 19, 2013.
Liyanage SS, Rahman B, Ridda I, Newall AT, Tabrizi SN, Garland SM, et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One. 2013. 8(7):e69238. [Medline]. [Full Text].
Nongenital Cutaneous Disease
HPV Type
Common warts (verrucae vulgaris)
1, 2, 4, 26, 27, 29, 41, 57, 65, 75-78
Plantar warts (myrmecias)
1, 2, 4, 60, 63
Flat warts (verrucae planae)
3, 10, 27, 28, 38, 41, 49
Butcher’s warts (common warts of people who handle meat, poultry, and fish)
1-4, 7, 10, 28
Mosaic warts
2, 27, 57
Ungual squamous cell carcinoma
16
Epidermodysplasia verruciformis (benign)
2, 3, 10, 12, 15, 19, 36, 46, 47, 50
Epidermodysplasia verruciformis (malignant or benign)
5, 8-10, 14, 17, 20-25, 37, 38
Nonwarty skin lesions
37, 38
Nongenital Mucosal Disease
HPV Type
6, 11
Squamous cell carcinoma of the lung
6, 11, 16, 18
Laryngeal papilloma (recurrent respiratory papillomatosis) [15]
2, 6, 11, 16, 30, 40, 57
6, 11
Maxillary sinus papilloma
57
Squamous cell carcinoma of the sinuses
16, 18
Conjunctival papillomas
6, 11
Conjunctival carcinoma
16
Oral focal epithelial hyperplasia (Heck disease)
13, 32
16, 18
16, 18
Squamous cell carcinoma of the esophagus
16, 18
Anogenital Disease
HPV Type
1-6, 10, 11, 16, 18, 30, 31, 33, 35, 39-45, 51-59, 70, 83
16, 18, 34, 39, 40, 42, 45
16, 18, 31, 34
Giant condylomata (Buschke-Löwenstein tumors)
6, 11, 57, 72, 73
Unspecified intraepithelial neoplasia
30, 34, 39, 40, 53, 57, 59, 61, 62, 64, 66-69
Low-grade squamous intraepithelial lesions (LGSIL)
6, 11, 16, 18, 26, 27, 30, 31, 33-35, 40, 42-45, 51-58, 61, 62, 67-69, 71-74, 79, 81-84
High-grade squamous intraepithelial lesions (HGSIL)
6, 11, 16, 18, 31, 33, 35, 39, 42, 44, 45, 51, 52, 56, 58, 59, 61, 64, 66, 68, 82
6, 11, 16, 18
Carcinoma of vagina
16
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73, 82
Carcinoma of anus
16, 31, 32, 33
Carcinoma in situ of penis (erythroplasia of Queyrat)
16
16, 18
Peter A Gearhart, MD Assistant Professor of Obstetrics and Gynecology, University of Pennsylvania School of Medicine
Peter A Gearhart, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists
Disclosure: Received honoraria from Merck for speaking and teaching.
Thomas C Randall, MD Associate Professor of Clinical Obstetrics and Gynecology University of Pennsylvania School of Medicine; Director, Gynecologic Oncology, Pennsylvania Hospital
Thomas C Randall, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American College of Obstetricians and Gynecologists
Disclosure: Nothing to disclose.
Roland Michael Buckley, Jr, MD Clinical Professor of Medicine, University of Pennsylvania School of Medicine; Consultant, Department of Medicine, Division of Infectious Diseases, Pennsylvania Hospital
Disclosure: Nothing to disclose.
Robert V Higgins, MD Clinical Associate Professor, Department of Obstetrics/Gynecology, University of North Carolina School of Medicine; Residency Program Director, Vice-Chairman of Academic Affairs, Associate Director of Gynecologic Oncology, Department of Obstetrics/Gynecology, Carolinas Medical Center
Robert V Higgins, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, North Carolina Medical Society, Society of Gynecologic Oncology, American College of Surgeons
Disclosure: Nothing to disclose.
Pranatharthi Haran Chandrasekar, MBBS, MD Professor, Chief of Infectious Disease, Department of Internal Medicine, Wayne State University School of Medicine
Pranatharthi Haran Chandrasekar, MBBS, MD is a member of the following medical societies: American College of Physicians, American Society for Microbiology, International Immunocompromised Host Society, Infectious Diseases Society of America
Disclosure: Nothing to disclose.
Jeffrey D Band, MD Professor of Medicine, Oakland University William Beaumont School of Medicine; Director, Division of Infectious Diseases and International Medicine, Corporate Epidemiologist, William Beaumont Hospital; Clinical Professor of Medicine, Wayne State University School of Medicine
Disclosure: Nothing to disclose.
Ryan Brashear, MD Staff Physician, Department of Dermatology, Indiana University School of Medicine
Ryan Brashear, MD is a member of the following medical societies: American Academy of Dermatology and American Medical Association
Disclosure: Nothing to disclose.
David F Butler, MD Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: Nothing to disclose.
Edward F Chan, MD Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine
Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.
Tsu-Yi Chuang, MD, MPH Clinical Professor, Department of Dermatology, Keck School of Medicine of the University of Southern California; Staff Dermatologist, Desert Oasis Healthcare
Tsu-Yi Chuang, MD, MPH is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, and International Society of Dermatology
Disclosure: Nothing to disclose.
Mark W Cobb, MD Consulting Staff, WNC Dermatological Associates
Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and American Society of Dermatopathology
Disclosure: Nothing to disclose.
Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.
Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose
Ronald A Greenfield, MD Professor, Department of Internal Medicine, University of Oklahoma College of Medicine
Ronald A Greenfield, MD is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Central Society for Clinical Research, Infectious Diseases Society of America, Medical Mycology Society of the Americas, Phi Beta Kappa, Southern Society for Clinical Investigation, and Southwestern
Disclosure: Pfizer Honoraria Speaking and teaching; Gilead Honoraria Speaking and teaching; Ortho McNeil Honoraria Speaking and teaching; Abbott Honoraria Speaking and teaching; Astellas Honoraria Speaking and teaching; Cubist Honoraria Speaking and teaching; Forest Pharmaceuticals Speaking and teaching
Mary D Nettleman, MD, MS, MACP Professor and Chair, Department of Medicine, Michigan State University College of Human Medicine
Mary D Nettleman, MD, MS, MACP is a member of the following medical societies: American College of Physicians, Association of Professors of Medicine, Central Society for Clinical Research, Infectious Diseases Society of America, and Society of General Internal Medicine
Disclosure: Nothing to disclose.
Charles V Sanders, MD Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine at New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center
Charles V Sanders, MD is a member of the following medical societies: Alliance for the Prudent Use of Antibiotics, Alpha Omega Alpha, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, American College of Physician Executives, American College of Physicians, American Federation for Medical Research, American Foundation for AIDS Research, American GeriatricsSociety, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association for Professionals in Infection Control and Epidemiology, Association of American Medical Colleges, Association of American Physicians, Association of Professors of Medicine, Infectious Disease Society for Obstetrics and Gynecology, Infectious Diseases Societyof America, Louisiana State Medical Society, Orleans Parish Medical Society, Royal Society of Medicine, Sigma Xi, Society of General Internal Medicine, Southeastern Clinical Club, Southern Medical Association, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology
Disclosure: Nothing to disclose.
John D Shanley, MD, MPH Professor Emeritus, University of Connecticut; Professor of Preventive Medicine, Stony Brook Medical Center
John D Shanley, MD, MPH is a member of the following medical societies: American Association for the Advancement of Science, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Medscape Salary Employment
Human Papillomavirus (HPV)
Research & References of Human Papillomavirus (HPV)|A&C Accounting And Tax Services
Source
0 Comments